



岐阜大学機関リポジトリ

Gifu University Institutional Repository

Title	PJ-138 New Sesquiterpene Lactone Compared with Rapamycin Inhibits Migration Rather than Proliferation in Rat Vascular Smooth Muscle Cells(本文(Fulltext))
Author(s)	NAKAGAWA, Munehiro; OHNO, Takamasa; MARUYAMA, Rumi; TAKEMURA, Genzou; MINATOBUCHI, Shinya; FUJIWARA, Hisayoshi
Citation	[Circulation journal : official journal of the Japanese Circulation Society] vol.[70] no.[Suppl. 1] p.[523]-[523]
Issue Date	2006-03-01
Rights	The Japanese Circulation Society (社団法人日本循環器学会)
Version	出版社版 (publisher version) postprint
URL	http://hdl.handle.net/20.500.12099/35064

この資料の著作権は、各資料の著者・学協会・出版社等に帰属します。

ployment. Overall TLR of SES was significantly smaller than that of BMS (15% vs. 48%, $p < 0.0001$). In lesion length of < 20 mm, there was no significant difference between two groups (18% vs. 42% $p = 0.0567$), but TLRs of SG were significantly smaller than those of BMS, in the lesion length of > 20 mm (5% vs. 50%, $p = 0.0037$), in all sizes of stent diameter (2.5mm: 2.8% vs. 14% $p = 0.0495$, > 3.0 mm: 9.1% vs. 51% $p < 0.001$) and in bifurcation lesion (15% vs. 60%: $p = 0.0071$). Conclusion: SES reduced TLR in longer lesion than 20mm, small vessel disease and bifurcation lesion even in diabetic patients comparing BMS in Japan.

PJ-135

Comparison between Women and Men in Vessel Dimension, Plaque Burden and Restenosis Assessed by Intracoronary Ultrasound (IVUS) and Quantitative Coronary Angiography (QCA)

¹Yasuo Kuroda

²Yukio Ozaki, ³Tatsuya Yasukawa, ⁴Katsuhisa Waseda,

¹Hiroaki Takashima, ¹Kenji Asai, ¹Yoshinori Wakita,

¹Takashi Kohsaka, ¹Yasushi Kuhara, ²Hitoshi Hishida, ²Takayuki Itoh

¹Department of Cardiology, Aichi Medical University, Nagakute, ²Division of Cardiology, Fujita Health University, Toyoake, ³Yasukawa Clinic, Nagoya, ⁴Center for Research in Cardiovascular Interventions Stanford University Medical Center, U.S.A

Background: Although it is commonly believed that women have a worse mortality than men after coronary intervention, the precise mechanism is still unknown. Methods: We examined the influence of gender difference on vessel dimension, plaque burden and restenosis in 574 patients undergoing IVUS-guided coronary stenting. Vessel area (VA), lumen area (LA) and plaque area (PLA=VA minus LA) were determined by IVUS. Of the 574 patients, 118 patients were women. Restenosis was defined as $> 50\%$ diameter stenosis (%DS) at follow-up. Conclusions: Although several baseline features were different between women and men, restenosis rate was similar. While angiographic vessel size was not different, IVUS revealed significantly greater vessel size associated with greater plaque burden. Greater plaque burden in men could result in similar restenosis rate to women after IVUS-guided coronary stenting.

Results:

	Women (n=118pts)	Men (n=456pts)	P
Age	65 ± 9	60 ± 10	<0.01
Hypertension (%)	59	47	<0.01
Diabetes (%)	40	25	<0.01
Hyperlipidemia (%)	55	43	<0.01
Smoking history (%)	30	75	<0.01
QCA			
RD* pre (mm)	2.76 ± 0.44	2.82 ± 0.51	n.s.
%DS pre	65 ± 10	65 ± 11	n.s.
%DS post	21 ± 8	20 ± 8	n.s.
%DS follow-up	39 ± 15	37 ± 18	n.s.
Restenosis rate (%)	23	19	n.s.
IVUS			
VA pre (mm ²)	12.1 ± 3.5	14.2 ± 4.7	<0.01
PLA pre (mm ²)	10.3 ± 3.6	12.3 ± 4.5	<0.01

*RD = reference diameter

PJ-136

Impact of Sirolimus-eluting Stent Implantation on Positive Remodeling Lesions in Patients with Coronary Artery Disease

Atsushi Iwata

Kazuyuki Shirai, Hiroaki Nishikawa, Hideya Niinura, Bo Zhang,

Kunihiko Matsuo, Shin-ichiro Miura, Keijiro Saku

Department of Cardiology, Fukuoka University School of Medicine, Fukuoka

Objectives: Since recent studies demonstrated that positive remodeling and a pre-interventional plaque burden influence the development of intimal hyperplasia after bare-metal stent implantation, we investigated whether the plaque burden influences late lumen loss after sirolimus-eluting stent (SES) implantation in a de novo lesion with positive remodeling. Methods: We examined 24 consecutive positive remodeling lesions in patients with SES implantation under intravascular ultrasound (IVUS) guidance. Quantitative coronary angiography analysis was performed at baseline and 6-month follow-up, and IVUS assessment was performed before the intervention. A remodeling index (RI) was

defined as the vessel area at the target lesion divided by that of the averaged reference segments. Results: The percentage of target-lesion revascularization was 4.2%, and in-segment late lumen loss was 0.04 ± 0.31 mm. Plaque area (PA, 9.2 ± 3.0 mm²) and %PA (plaque area/vessel area, $75.7 \pm 5.0\%$) at the lesion site did not correlate with late lumen loss, and the late lumen loss also did not correlate with RI. Moreover, volumetric IVUS assessment revealed that plaque volume (PV, 210.2 ± 111.8 mm³) and %PV (plaque volume/vessel volume, $67.1 \pm 7.0\%$) showed no significant correlation with late lumen loss. Conclusions: SES is a useful strategy for addressing positive remodeling lesions, and the pre-interventional plaque burden had no effect on late lumen loss after SES implantation. Therefore, directional coronary atherectomy may not be required for positive remodeling before SES implantation.

PJ-137

Comparing Sirolimus-eluting Stent Implantation and Cutting Balloon for Prevention of Recurrences in Patients with In-stent Restenosis

Mitsuru Tanaka

Mitsuhiro Shimomura, Katsumasa Nomura, Akihiko Matsuyama,

Shuji Hirano, Yoshitatsu Nagatomo, Yoshisato Shibata, Takao Ayabe

Department of Cardiology, Miyazaki medical association hospital, Miyazaki

Objective: To assess if drug-eluting stents are a more effective treatment for in-stent restenosis than balloon angioplasty using the cutting balloon device. Methods: We retrospectively analyzed 316 consecutive patients with angiographically significant in-stent restenosis. We divided the patients into 2 treatment groups: the cutting group (n=234), patients treated with the cutting balloon device for in-stent restenosis from March 1, 1998 to June 30, 2004, and the drug-eluting stent (DES) group (n=82), patients treated with DES for in-stent restenosis from July 1, 2004 to September 30, 2005. We compared the rate of recurrent restenosis and target lesion revascularization (TLR) between the two groups. Results: The initial success rate (residual diameter stenosis of $< 50\%$ in the target lesion) was achieved 100% of the time in both groups. Reference vessel diameter was 2.71 ± 0.61 mm in the cutting group and 2.57 ± 0.76 mm in the DES group ($p = 0.10$). Follow-up angiography was performed in 272 of 316 (86.1%) patients. Angiographic restenosis rate was 34.4% (74/215) in the cutting group and 3.5% (2/57) in the DES group ($p < 0.05$). The TLR was 21.4% (46/215) in the cutting group and 3.5% (2/57) in the DES group ($p < 0.05$). Conclusions: In patients with in-stent restenosis, a strategy based on sirolimus-eluting stents is superior to cutting balloon angioplasty for the prevention of recurrent restenosis.

PJ-138

New Sesquiterpene Lactone Compared with Rapamycin Inhibits Migration Rather than Proliferation in Rat Vascular Smooth Muscle Cells

¹Munehiro Nakagawa

²Takamasa Ohno, ¹Rumi Maruyama, ¹Genzou Takemura,

¹Shinya Minatoguchi, ¹Hisayoshi Fujiwara

¹Department of Cardiology, Gifu University Graduate School of Medicine, Gifu,

²Department of Oriental Medicine, Gifu University School of Medicine, Gifu

Abnormal vascular smooth muscle cell (VSMC) proliferation and migration play major roles in the development of restenosis after percutaneous transluminal coronary angioplasty. Previously we reported anticancer effects of the water extract of the root of *Lindera strychnifolia* (LS), a herbal medicine. Recently we isolated new sesquiterpene lactone (compound 1) from the root of LS with antiproliferative activity against human small cell lung cancer cells. The present study was designed to characterize the effects of compound 1 on proliferation and migration in cultured rat VSMC. When the time course of cell proliferation was examined at a concentration of 1μ g/ml, compound 1 inhibited the proliferation. The degree of inhibition was similar to that of 100ng/ml of rapamycin, which is used in Cypher, drug-eluting stents (DES). Furthermore, compound 1 as well as rapamycin inhibited the cell cycle progression at G₀/G₁ phase. On the other hand, PDGF-induced migration in modified Boyden chamber method (PDGF-BB homodimer; 20 ng/ml) for 48h was markedly inhibited by pretreatment with compound 1 (3.3 ± 1.3 (% of the control)) but mildly by rapamycin (64.3 ± 6.7 (% of the control)). Compound 1 did not show significant cytotoxicity until 48 h. These results suggest that compound 1 may be promising candidate for the new drug in the form of DES, which is different from rapamycin.